TBPMF News and Press, Tetra Bio-Pharma Inc From 01/24/21

Cannabis sales are determined by number of dispensaries and the availability to them by proximity. California has no restrictions regarding the number of dispensaries such as Washington State. Growth in cannabis in California will eclipse the entire cannabis industry's current ret...

Cannabis companies are starting to turn a profit and print positive EPS. Here are the few that are earning a profit. Many companies are close to turning a positive EPS. The industry itself is expected to expand some 100% in the next couple of years, and with economies of scale, th...

Both Senate seats went to Democrats and this allows for a blue agenda with cannabis legalization being one of the top priorities. Arizona's legalization of recreational cannabis is already being geared up for with companies retooling in preparation. The industry will see continued...

2020 saw increases of 80% in Canada and expectations are for that to double next year. California will lead revenue growth rates as the state continues to ramp up the industry. Washington and Colorado are starting to see overall growth rates slow modestly, excepting pandemic-induc...

The addressable market is estimated to be $80M CDN by 2022 Tetra meets another key milestone before the end of the year OTTAWA, ON / ACCESSWIRE / December 30, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") ( TSX:TBP )( OTCQB:TBPMF ), a leader in cannabinoid-derived dru...

Tetra Provides Update on ARDS-003 Tetra Eyes Global Sepsis Market OTTAWA, ON / ACCESSWIRE / December 21, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") ( TSX:TBP )( OTCQB:TBPMF ), a leader in cannabinoid-derived drug discovery and development, today announced that it e...

Tetra will accelerate its Inhaled synthetic THC drug approvals under a 505(b)(2) marketing application pathway FDA confirms clinical development program to support marketing application of Tetra's inhaled innovative THC drug OTTAWA, ON / ACCESSWIRE / December 16, 2020 / Tetra Bi...

Tetra Estimates Net Sales reaching $675M USD by 2027 Tetra is evaluating potential commercial partners to launch QIXLEEF™ in USA OTTAWA, ON / ACCESSWIRE / December 7, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") ( TSX:TBP ) ( OTCQB:TBPMF ), a leader in cannab...

PATHWAY NOW CLEARED FOR HUMAN TRIALS OTTAWA, ON / ACCESSWIRE / December 2, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") ( TSX:TBP ) ( OTCQB:TBPMF ), a leader in cannabinoid-derived drug discovery and development, today announced it has completed Investigational New Drug (IN...

Plenitude Trial initiated Tetra completes clinical study assessing the metabolism profile of cannabinoids in humans Achieved development of ARDS-003 sterile injectable nano-emulsion for human use OTTAWA, ON / ACCESSWIRE / November 16, 2020 / Tetra Bio-Pharma Inc. ("Tetra" o...